Live from the NIH registry
Studies recruiting near Albuquerque right now
Top 25 of 345 recruiting studies, sorted by proximity — each links to its official registry page
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Lovelace Medical Center-Saint Joseph Square — Albuquerque, New Mexico (1.5 mi)
· Sponsor: SWOG Cancer Research Network
American Indian Chronic Renal Insufficiency Cohort Study (AI-CRIC Study)
Diabetes Mellitus, Chronic Kidney Diseases
N/A
Observational 500 participants sought
First Nations Community Health Source — Albuquerque, New Mexico (1.5 mi)
· Sponsor: University of New Mexico
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
Presbyterian Hospital — Albuquerque, New Mexico (1.5 mi)
· Sponsor: National Cancer Institute (NCI)
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis
Phase 2
Interventional 168 participants sought
R1 Therapeutics Clinical Trial Site — Albuquerque, New Mexico (1.5 mi)
· Sponsor: R1 Therapeutics
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma
Phase 2
Interventional 40 participants sought
Ohio State University-Telemedicine — Albuquerque, New Mexico (1.5 mi)
· Sponsor: Sameek Roychowdhury
Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial
Endometrial Endometrioid Adenocarcinoma, Endometrial Hyperplasia
Phase 2
Interventional 140 participants sought
University of New Mexico Cancer Center — Albuquerque, New Mexico (1.5 mi)
· Sponsor: New Mexico Cancer Research Alliance
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Plasma Cell Myeloma
Phase 3
Interventional 510 participants sought
Lovelace Medical Center-Saint Joseph Square — Albuquerque, New Mexico (1.5 mi)
· Sponsor: SWOG Cancer Research Network
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Phase 2
Interventional 140 participants sought
Optimum Clinical Research Group /ID# 274583 — Albuquerque, New Mexico (1.5 mi)
· Sponsor: AbbVie
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
Phase 3
Interventional 600 participants sought
Research Site — Albuquerque, New Mexico (1.5 mi)
· Sponsor: AstraZeneca
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Acute Myeloid Leukemia (AML)
Phase 3
Interventional 1,300 participants sought
University of New Mexico — Albuquerque, New Mexico (1.5 mi)
· Sponsor: Kura Oncology, Inc.
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Parkinson Disease
Phase 2
Interventional 150 participants sought
University of New Mexico Health Sciences Center (Site #225) — Albuquerque, New Mexico (1.5 mi)
· Sponsor: Appello Pharmaceuticals, Inc.
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
Prediabetic State, Atherosclerosis
Phase 4
Interventional 7,410 participants sought
New Mexico VA Health Care System, Albuquerque, NM — Albuquerque, New Mexico (1.5 mi)
· Sponsor: VA Office of Research and Development
C-Brace Prospective Registry
Pareses, Lower Extremity
N/A
Observational 250 participants sought
Raymond G. Murphy VA — Albuquerque, New Mexico (1.5 mi)
· Sponsor: Otto Bock Healthcare Products GmbH
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Multiple conditions
Phase 2
Interventional 150 participants sought
University of New Mexico Cancer Center — Albuquerque, New Mexico (1.5 mi)
· Sponsor: National Cancer Institute (NCI)
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 3
Interventional 1,145 participants sought
Research Site — Albuquerque, New Mexico (1.5 mi)
· Sponsor: AstraZeneca
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Phase 3
Interventional 1,530 participants sought
New Mexico Oncology Hematology Consultants Ltd. ( Site 0090) — Albuquerque, New Mexico (1.5 mi)
· Sponsor: Merck Sharp & Dohme LLC
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes
N/A
Observational 200 participants sought
University of New Mexico — Albuquerque, New Mexico (1.5 mi)
· Sponsor: Jaeb Center for Health Research
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Phase 2
Interventional 2,000 participants sought
University of New Mexico Cancer Center — Albuquerque, New Mexico (1.5 mi)
· Sponsor: National Cancer Institute (NCI)
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma
Phase 2
Interventional 396 participants sought
University of New Mexico Cancer Center — Albuquerque, New Mexico (1.5 mi)
· Sponsor: SWOG Cancer Research Network
The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry
Cesarean Delivery, General Anesthesia
N/A
Observational 5,000 participants sought
University of New Mexico — Albuquerque, New Mexico (1.5 mi)
· Sponsor: Yale University
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Diabetes Mellitus, Type 2, Hypertension
Phase 3
Interventional 11,800 participants sought
New Mexico Clinical Research and Osteoporosis Center, Inc. — Albuquerque, New Mexico (1.5 mi)
· Sponsor: Boehringer Ingelheim
Clinical Evaluation of Precision for the Potassium and Ionized Calcium Tests in Capillary Specimens
Hematologic Tests
N/A
Interventional 425 participants sought
University of New Mexico — Albuquerque, New Mexico (1.5 mi)
· Sponsor: Abbott Point of Care
Letrozole in Uterine Leiomyosarcoma
Uterine Leiomyosarcoma
Phase 2
Interventional 40 participants sought
University of New Mexico Comprehensive Cancer Center — Albuquerque, New Mexico (1.5 mi)
· Sponsor: GOG Foundation
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Phase 3
Interventional 1,875 participants sought
Presbyterian Hospital — Albuquerque, New Mexico (1.5 mi)
· Sponsor: National Cancer Institute (NCI)
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
IC-MPGN
Phase 3
Interventional 106 participants sought
University of New Mexico — Albuquerque, New Mexico (1.5 mi)
· Sponsor: Novartis Pharmaceuticals